Drug combination shows benefit for men with melanoma

A drug combination approved last year by the U.S. Food and Drug Administration may have a greater effect for men with melanoma than previously reported, according to a new analysis of clinical trial data.

Read the full story

Posted in Latest Research, FDA, case study

Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma

The field of melanoma recently gained an influx of immunotherapy approvals, and advancement in the field doesn’t seem to be slowing down. When the FDA expanded the drug’s label in December 2015, pembrolizumab (Keytruda) became the first anti–PD-1 therapy approved for previously untreated patients with advanced melanoma, regardless of BRAF status.

Read the full story

Posted in FDA, Cancer in the News

Nivolumab’s Growing Role in the Melanoma Treatment Paradigm –

In early February, the FDA granted expanded approval to nivolumab (Opdivo) as both a single agent, as well as in combination with ipilimumab (Yervoy), for patients with melanoma exhibiting BRAF V600 mutations. This expansion puts nivolumab in the frontline for all patients with advanced melanoma, which Jedd D. Wolchok, MD, PhD, says will be beneficial […]

Read the full story

Posted in Health Professionals, Patients Resources, FDA, Cancer in the News, Latest News

FDA expands Opdivo use for metastatic melanoma

FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma.

Read the full story

Posted in FDA, Cancer in the News

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories